Joaquin Duato sold $32M of JNJ
CEO and Chairman of the Board at JOHNSON & JOHNSON. 123,291 shares at an average of $261.17, traded Aug 13, 2026, filed Aug 14, 2026.
Score components
- +25RoleCEO
- +25Trade size$32.2M at market
- +10Share of holdings soldSold 31% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000200406-26-000173, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | MOption exercise Common Stock | +123,291 | $115.67 | $14M | 399,258 | Aug 14, 2026 |
| Aug 13, 2026 | SOpen-market sale Common Stock | -20,976 | $262.00 | $5.5M | 378,282 | Aug 14, 2026 |
| Aug 13, 2026 | SOpen-market sale Common Stock | -102,315 | $261.00 | $27M | 275,967 | Aug 14, 2026 |
| Aug 13, 2026 | MOption exercise Employee Stock Options (Right to Buy)derivative | -123,291 | $0.00 | $0 | 0 | Aug 14, 2026 |
Related signals
Other insiders at JOHNSON & JOHNSON and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | JNJsell JOHNSON & JOHNSON | Timothy Schmid EVP, WW Chair, MedTech | $9.2M 33,597 shares | -92% | |
| 40Moderate | JOHNSON & JOHNSON | Jennifer L Taubert EVP, WWC. Innovative Medicine | $4.0M 15,000 shares | -7% | |
| 70Notable | JOHNSON & JOHNSON | Joaquin Duato CEO and Chairman of the Board | $13M 48,480 shares | -15% | |
| 50Moderate | JOHNSON & JOHNSON | Elizabeth Forminard EVP, Chief Legal Officer | $4.1M 15,918 shares | -48% | |
| 45Moderate | JNJsell JOHNSON & JOHNSON | Vanessa Broadhurst EVP, Global Corp Affairs | $5.8M 23,054 shares | -50% | |
| 25Weak | JNJsell JOHNSON & JOHNSON | Kathryn E Wengel EVP, Chief TO and Risk Officer | $2.4M 10,000 shares | -8% | |
| 45Moderate | JOHNSON & JOHNSON | Robert J Decker VP Corporate Controller | $1.0M 4,075 shares | -15% | |
| 49Moderate | JOHNSON & JOHNSON | Timothy Schmid EVP, WW Chair, MedTech | $325k 1,322 shares | -5% | |
| 45Moderate | JOHNSON & JOHNSON | Vanessa Broadhurst EVP, Global Corp Affairs | $1.5M 6,197 shares | -21% | |
| 65Notable | JOHNSON & JOHNSON | Timothy Schmid EVP, WW Chair, MedTech | $5.5M 22,623 shares | -56% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.